Skip to main content

Comparison of clinical outcome with oral and inhaled bronchodilators in the management of wheezy children aged 1–59 months in the community: a randomised trial in Pakistan

Buy Article:

$34.78 + tax (Refund Policy)

BACKGROUND: Wheeze is a significant problem in children. There is a gradual trend of switching from oral to inhaled bronchodilator therapy. No randomised trials have been carried out in the community to compare the clinical outcome of two modes of therapy. If outcome with oral and inhaled bronchodilators is the same in young wheezers in developing countries, it will be easier to manage them.

METHODS: In a randomised multicentre trial, wheezy children aged 1–59 months with fast breathing and/or lower chest indrawing received oral or inhaled salbutamol at home after responding to up to three cycles of inhaled bronchodilators. They were re-assessed on days 3 and 5 for clinical outcome.

RESULTS: From May 2001 to August 2002, 780 children were enrolled; 390 each were randomised to oral and inhaled salbutamol. On day 5, 324 (83.1%) children in the oral and 328 (84.1%) in the inhaled group were completely well. There were no differences in clinical outcome of both modes of therapy.

CONCLUSIONS: The clinical outcome of children aged 1–59 months with wheeze is similar when treated with oral or inhaled salbutamol. Acute respiratory infection control programmes in developing countries should continue to use oral bronchodilators for the management of wheeze to save both time and money.

Keywords: child; metered dose inhaler; oral salbutamol; wheezing

Document Type: Regular Paper

Affiliations: 1: The Children's Hospital, Pakistan Institute of Medical Sciences, Islamabad, Pakistan 2: Department of Child and Adolescent Health and Development, World Health Organization, Geneva, Switzerland 3: Children's Hospital, Lahore, Punjab, Pakistan 4: Department of Paediatrics, Rawalpindi General Hospital, Rawalpindi, Punjab, Pakistan

Publication date: 01 November 2004

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content